CD8A and neoplasm: Several clinical trials, applied to pancreatic, prostate, liver, and kidney tumors indicate that IRE is associated with varying degrees of clinical success40–44, and recent studies in both humans and mice suggest an overall increase in tumor infiltration of bulk CD8+ T cells45–47.